Saturday 17 October 2026
Export GH’s income statement to Excel — free account
Guardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024. In the quarter to June 2026, revenue grew 44.3%, EPS fell 12.5%, free cash flow fell 5.46% and total debt rose 34.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
158.29
7.59
−4.58%
Follow GH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
16.85 | 11.23 | 13.04 | 8.64 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(345.01) | (184.78) | (485.56) | (220.20) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
17.23 | 11.60 | 13.35 | 9.23 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(110.07) | (66.74) | (70.95) | (37.38) | |
EV/FCF |
(78.82) | (49.12) | (52.23) | (29.75) | |
Quick Ratio |
3.53 | 4.25 | 4.42 | 2.94 | |
Current Ratio |
4.03 | 4.68 | 4.84 | 3.50 | |
Net Debt/EBITDA |
(3.73) | (3.37) | (2.59) | (6.02) | |
Debt/Assets |
78.59% | 78.50% | 74.69% | 87.30% | |
Debt/Equity |
(6.74) | (8.30) | (15.14) | (3.14) | |
Asset Turnover |
0.73 | 0.66 | 0.56 | 0.64 | |
Operating CF/Net income |
0.48 | 0.59 | 0.21 | 0.38 | |
Capex/Depreciation |
(1.37) | (2.27) | (6.67) | (1.01) | |
Interest Coverage |
(95.93) | (90.09) | (102.38) | (104.97) | |
Research and Development Expense of Revenue |
28.82% | 30.18% | 34.94% | 33.92% | |
Selling, General and Administrative Expense of Revenue |
75.11% | 75.27% | 72.64% | 68.12% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.01 | |
Share Based Compensation of Revenue |
17.23% | 15.78% | 15.36% | 16.14% | |
Graham Net Nets |
(0.04) | (0.06) | (0.05) | (0.10) | |
Graham Number |
11.48 | 10.26 | 7.68 | 14.32 | |
Earnings Yield |
(2.33%) | (3.67%) | (3.24%) | (5.14%) | |
Free Cash Flow Yield |
(1.30%) | (2.10%) | (1.96%) | (3.59%) | |
Revenue per Share |
2.52 | 2.30 | 2.24 | 2.12 | |
Operating CF per Share |
(0.43) | (0.50) | (0.21) | (0.28) | |
Capex per Share |
(0.09) | (0.04) | (0.22) | (0.08) | |
Free Cash Flow per Share |
(0.52) | (0.54) | (0.43) | (0.37) | |
Cash per Share |
7.93 | 8.40 | 9.58 | 4.65 | |
Shareholders Equity per Share |
(1.68) | (1.38) | (0.79) | (2.84) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.68) | (1.38) | (0.79) | (2.84) | |
Free Cash Flow |
(69.54) | (71.20) | (54.22) | (45.76) | |
Working Capital |
1,025.68 | 1,075.36 | 1,163.32 | 591.97 | |
Capital Expenditures |
(11.76) | (5.58) | (27.85) | (10.35) | |
Net Current Asset Value |
(770.52) | (728.86) | (646.92) | (802.37) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.02 | 0.10 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
137.25 | 126.42 | 124.05 | 102.03 | |
Average Payables |
69.16 | 62.40 | 46.50 | 17.81 | |
Average Inventory |
94.76 | 80.55 | 78.48 | 81.39 | |
Average Assets |
1,622.15 | 1,629.76 | 1,749.63 | 1,407.76 | |
Average Common Equity |
(264.17) | (215.93) | (119.48) | (207.28) |
Columns are period end dates